The beleaguered drug maker held a lengthy and much-anticipated briefing on Tuesday for investors, and the news wasn’t pretty — the company cut its 2016 revenues and earnings forecast more than expected and disclosed weakness in areas of its business that caught investors by surprise. Particularly disturbing is the possibility that Valeant is in danger of defaulting on some of its debt.
Read Full Article »
